PRSS33 Antibody

What is PRSS33 and what are its key functional characteristics?

PRSS33, also known as Serine protease 33 or Serine protease EOS, is a serine protease that demonstrates amidolytic activity, specifically cleaving its substrates before arginine residues . It belongs to the peptidase S1 family (EC 3.4.21.-) and functions as a secreted protein with a signal peptide . The human PRSS33 protein (UniProt ID: Q8NF86) has a molecular weight of approximately 29,787 Da and is encoded by a gene located on chromosome 16p13.3 . This protease likely plays roles in proteolytic pathways involved in digestion, inflammation, and tissue remodeling processes . Sequence analysis reveals moderate conservation across species, with approximately 71% identity to mouse orthologs and 73% identity to rat orthologs .

What types of PRSS33 antibodies are currently available for research applications?

Research-grade PRSS33 antibodies are available in several formats:

Researchers can select antibodies based on their experimental needs, with polyclonal antibodies offering broader epitope recognition while monoclonal antibodies provide greater epitope specificity . Both types of antibodies are typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide . For specialized detection, immunogen sequences such as "RALPAEYRVR LGALRLGSTS PRTLSVPVRR VLLPPDYSED GARGDLALLQ LR" are used to generate antibodies with specific recognition patterns .

What are the validated applications for PRSS33 antibodies in research?

PRSS33 antibodies have been validated for multiple research applications:

• Western Blot (WB): Typically used at dilutions of 1:500-1:2000 to detect both the full-length PRSS33 protein and its processed forms in cell and tissue lysates .

• Immunohistochemistry (IHC): Recommended dilutions range from 1:100-1:300 for detecting PRSS33 in fixed tissue sections, allowing for localization studies and expression analysis across different tissues and disease states .

• ELISA: Used for quantitative measurement of PRSS33 levels in biological fluids such as serum, which can be particularly valuable for biomarker studies .

• Immunoprecipitation: While less commonly reported, antibodies can be used to isolate PRSS33 from complex protein mixtures for downstream analysis .

Research has demonstrated that using multiple antibodies targeting different regions of PRSS33 can provide complementary information, particularly when studying processed forms of the protein that may result from proteolytic cleavage .

How should I optimize Western blot protocols for detecting different forms of PRSS33?

Optimizing Western blot protocols for PRSS33 detection requires careful consideration of several factors:

• Sample preparation: When studying PRSS33, it's essential to consider both intracellular (full-length) and extracellular (secreted/processed) forms. Research has shown that the molecular weight of PRSS33 enriched in culture medium (secreted form) is significantly lower than that of full-length PRSS33 isolated from cell lysates . Therefore:

  • For cell lysates: Use RIPA buffer with protease inhibitors to preserve the full-length protein

  • For conditioned media: Consider TCA precipitation or ultrafiltration to concentrate secreted forms

• Antibody selection: Use antibodies targeted to different peptide regions of PRSS33 to detect various processed forms. Studies have utilized antibodies designated based on their respective antigen sequences (N-terminal, middle, or C-terminal) to reveal multiple short forms of PRSS33 protein .

• Gel percentage: Use 10-12% gels for full-length PRSS33 (29.8 kDa) and 15-18% gels when attempting to resolve smaller processed fragments.

• Blocking and antibody dilution: 5% non-fat milk in TBST is typically effective for blocking, with primary antibody dilutions of 1:500-1:2000 providing optimal results. Overnight incubation at 4°C often yields cleaner results than shorter incubations .

• Validation approach: Include positive controls (recombinant PRSS33) and negative controls (lysates from cells known not to express PRSS33) to verify specificity .

What are the critical considerations for designing PRSS33 antibody-based immunohistochemistry experiments?

Successful immunohistochemistry using PRSS33 antibodies requires attention to several methodological details:

• Tissue fixation and antigen retrieval: Most PRSS33 antibodies perform optimally with formalin-fixed, paraffin-embedded tissues. Heat-induced epitope retrieval using citrate buffer (pH 6.0) is typically effective, though some epitopes may require EDTA buffer (pH 9.0) .

• Antibody dilution and incubation: Start with the manufacturer's recommended dilution range (typically 1:100-1:300) and optimize based on your specific tissue . Overnight incubation at 4°C often provides optimal staining with minimal background.

• Detection system selection: For low-abundance targets like PRSS33, amplification systems such as polymer-based detection methods may provide superior sensitivity compared to traditional ABC methods.

• Counterstaining considerations: PRSS33 expression patterns can vary by tissue type and disease state. Studies have shown gradual reduction in PRSS33 levels with increasing stage of hepatocellular carcinoma development, suggesting its potential as a prognostic marker . When analyzing such patterns, appropriate counterstaining is crucial for accurate interpretation.

• Validation approaches:

  • Positive controls: Include tissues known to express PRSS33

  • Negative controls: Omit primary antibody or use isotype control

  • Competing peptide controls: Pre-incubate antibody with immunogen peptide to confirm specificity

  • Correlation with other methods: Compare IHC results with Western blot or qPCR data from the same samples

How can I establish robust ELISA protocols for quantifying PRSS33 in biological samples?

Establishing reliable ELISA protocols for PRSS33 quantification requires:

• Antibody pair selection: For sandwich ELISA, select antibodies recognizing different epitopes of PRSS33. Research has demonstrated success with customized PRSS33 ELISA kits using two antibodies against the N-terminal region .

• Standard curve preparation: Use recombinant PRSS33 protein to generate standard curves, ensuring the protein contains the epitopes recognized by your antibodies. Include a broad range of concentrations (typically 0-1000 pg/ml) to accommodate varying expression levels.

• Sample preparation considerations:

  • Serum/plasma: Studies have shown that levels of truncated PRSS33 forms, but not full-length PRSS33, can be markedly altered in disease states such as hepatocellular carcinoma . Therefore, sample dilution optimization is crucial.

  • Cell culture supernatants: May require concentration depending on expression levels

  • Tissue lysates: Require optimization of extraction buffers to solubilize PRSS33 efficiently

• Assay validation parameters:

  • Specificity: Test cross-reactivity with related serine proteases

  • Sensitivity: Determine lower limit of detection

  • Reproducibility: Assess intra- and inter-assay variation

  • Recovery: Spike known amounts of recombinant PRSS33 into samples

  • Linearity: Test serial dilutions of samples to confirm parallel curves with standards

• Data normalization: For tissue samples, normalize PRSS33 measurements to total protein concentration to account for variations in sample preparation.

How can computational approaches enhance PRSS33 antibody design and specificity?

Computational methods offer powerful tools for designing PRSS33 antibodies with customized specificity profiles:

• Mode-based modeling approaches: Advanced computational models can be developed to identify different antibody binding modes, each associated with particular ligands. Research has demonstrated that such models can successfully disentangle these modes, even when associated with chemically very similar ligands .

• Customized specificity profile design: Computational approaches enable the design of antibodies with:

  • Specific high affinity for PRSS33 while excluding related serine proteases

  • Cross-specificity for multiple target epitopes when desired

• Energy function optimization: Generating new antibody sequences relies on optimizing energy functions associated with each binding mode:

  • For cross-specific sequences: Jointly minimize the energy functions associated with desired ligands

  • For highly specific sequences: Minimize energy functions for desired ligands while maximizing those for undesired ligands

• Implementation methodology:

  • Begin with phage display experimental data to train computational models

  • Identify key binding residues for PRSS33 recognition

  • Design and test variants not present in the training set

  • Validate computational predictions experimentally

• Limitations and considerations:

  • Model accuracy depends on quality and diversity of training data

  • Sequence-based predictions should be complemented with structural information when available

  • Amplification biases and codon-level selection effects should be evaluated

This approach has been successfully applied to design antibodies with customized specificity profiles, demonstrating the potential to develop PRSS33 antibodies with enhanced specificity or controlled cross-reactivity with related serine proteases .

What are the challenges in distinguishing PRSS33 from other closely related serine proteases?

Distinguishing PRSS33 from other serine proteases presents several challenges:

• Sequence homology issues: Serine proteases share conserved catalytic domains and similar structural features, making specific antibody generation challenging. For example, PRSS33 shares sequence homology with other members of the peptidase S1 family .

• Cross-reactivity assessment: Comprehensive testing against related proteases is essential:

  Related Protease	Homology to PRSS33	Distinguishing Features	Cross-reactivity Risk
  PRSS35	Moderate	Different substrate specificity	Medium
  Trypsin-like proteases	Variable	Similar catalytic mechanism	High
  Other EOS family members	High	Tissue distribution differences	Very high

• Epitope selection strategy: Target unique regions of PRSS33 that diverge from related proteases. The immunogen sequence "RALPAEYRVR LGALRLGSTS PRTLSVPVRR VLLPPDYSED GARGDLALLQ LR" has been used successfully to generate specific antibodies .

• Validation approaches:

  • Knockout/knockdown controls: Use PRSS33-deficient samples to confirm antibody specificity

  • Competitive binding assays: Pre-incubate antibodies with recombinant PRSS33 and related proteases

  • Mass spectrometry confirmation: Verify the identity of immunoprecipitated proteins by MS analysis

• Differential detection of processed forms: Research has shown that PRSS33 can be cleaved at specific sites, generating multiple fragments. Using antibodies targeting different regions can help distinguish these fragments and avoid confusion with related proteases .

How does PRSS33 expression vary across different tissues and disease states?

Understanding PRSS33 expression patterns is crucial for proper experimental design and data interpretation:

• Normal tissue distribution: PRSS33 shows a tissue-specific expression pattern, with significant expression observed in selected tissues. The protein exists in both full-length intracellular forms and processed secreted forms, with the latter showing distinct molecular weights in Western blot analysis .

• Disease-associated expression changes: Research indicates substantial alterations in PRSS33 expression in certain pathological conditions:

  • Cancer: Studies on related serine proteases (PRSS35) have shown markedly decreased expression in hepatocellular carcinoma compared to adjacent non-cancerous tissues, with gradual reduction correlating with increasing cancer stage . Similar patterns may exist for PRSS33.

  • Inflammation: As a serine protease, PRSS33 may participate in inflammatory processes, though specific expression changes require further investigation .

• Secreted vs. intracellular forms: The molecular weight of PRSS33 enriched in culture medium (secreted form) is significantly lower than full-length PRSS33 isolated from cell lysates, suggesting proteolytic processing during secretion . This processing may vary by tissue type and physiological state.

• Prognostic significance: For related proteases like PRSS35, patients expressing high levels in their cancer lesions exhibited much longer survival times than those with low expression . This suggests potential prognostic relevance for PRSS33 as well.

• Experimental approach considerations:

  • Use multiple antibodies targeting different regions to distinguish processed forms

  • Consider both tissue and serum/plasma levels for comprehensive analysis

  • Correlate protein expression with mRNA levels to identify post-transcriptional regulation

What are common issues when working with PRSS33 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with PRSS33 antibodies:

• Multiple band detection in Western blots:

  • Issue: Detection of multiple bands of varying molecular weights.

  • Explanation: This often reflects natural processing of PRSS33, as research has demonstrated that PRSS33 can be cleaved at specific sites, generating multiple fragments .

  • Solution: Use antibodies targeting different regions of PRSS33 to identify specific fragments. Studies have utilized N-terminal, middle, and C-terminal targeted antibodies to characterize different processed forms .

• Weak or absent signal:

  • Issue: Poor detection despite expected PRSS33 expression.

  • Causes and solutions:

    • Antibody sensitivity: Increase antibody concentration or use more sensitive detection methods

    • Protein degradation: Ensure fresh samples and appropriate protease inhibitors

    • Antigen masking: Optimize antigen retrieval for IHC or denaturation for Western blot

    • Low expression: Concentrate samples or use amplification systems

• High background in immunohistochemistry:

  • Issue: Non-specific staining obscuring specific signal.

  • Solutions:

    • Increase blocking duration (5% BSA or normal serum)

    • Optimize antibody dilution (typically 1:100-1:300)

    • Include additional washing steps

    • Use more specific detection systems

• Discrepancies between different antibodies:

  • Issue: Different results with antibodies targeting different regions of PRSS33.

  • Explanation: This may reflect differential detection of processed forms.

  • Solution: Integrate data from multiple antibodies for comprehensive analysis .

• Cross-reactivity concerns:

  • Issue: Potential recognition of related serine proteases.

  • Solutions:

    • Validate with PRSS33-deficient controls

    • Perform peptide competition assays

    • Compare results with orthogonal techniques (e.g., mass spectrometry)

How can I validate PRSS33 antibody specificity for my particular application?

Rigorous validation of PRSS33 antibody specificity requires a multi-faceted approach:

• Positive and negative controls:

  • Positive controls: Use cells/tissues known to express PRSS33 or recombinant PRSS33 protein

  • Negative controls:

    • Knockout/knockdown samples if available

    • Tissues known not to express PRSS33

    • Primary antibody omission controls

• Peptide competition assays:

  • Pre-incubate antibody with the immunogen peptide (e.g., "RALPAEYRVR LGALRLGSTS PRTLSVPVRR VLLPPDYSED GARGDLALLQ LR")

  • Observe signal elimination or reduction

  • Include control peptides to confirm specificity

• Multiple antibody concordance:

  • Compare results using antibodies targeting different epitopes

  • Consistent findings across antibodies increase confidence in specificity

• Orthogonal technique confirmation:

  • Correlate protein detection with mRNA expression

  • Confirm protein identity by mass spectrometry after immunoprecipitation

  • Compare with published expression databases

• Application-specific validation:

  • For Western blot: Verify expected molecular weight(s), including processed forms

  • For IHC: Confirm expected subcellular localization and tissue distribution

  • For ELISA: Demonstrate linearity, recovery, and parallelism with standard curves

What are the best practices for interpreting contradictory PRSS33 expression data?

When faced with conflicting PRSS33 expression data, apply these systematic interpretation strategies:

• Antibody considerations:

  • Epitope differences: Antibodies targeting different regions may detect distinct processed forms of PRSS33. Research has shown that using N-terminal, middle, and C-terminal antibodies can reveal different PRSS33 variants .

  • Specificity profiles: Evaluate cross-reactivity potential with related serine proteases

  • Sensitivity thresholds: Consider detection limits for different methods

• Sample preparation variables:

  • Processing methods: Different extraction protocols may preferentially recover certain PRSS33 forms

  • Storage conditions: Protein degradation can affect detection

  • Post-translational modifications: Consider how modifications might affect epitope accessibility

• Biological context variables:

  • Cell/tissue heterogeneity: PRSS33 expression may vary across cell types within samples

  • Disease state progression: Expression can change with disease progression, as demonstrated for related proteases in hepatocellular carcinoma

  • Transcriptional vs. post-transcriptional regulation: Compare protein and mRNA levels

• Methodological approach to reconciliation:

  • Triangulate with multiple techniques: Combine WB, IHC, ELISA, and mRNA analysis

  • Quantitative analysis: Use appropriate normalization and statistical methods

  • Consider processed forms: Evaluate total PRSS33 vs. specific processed variants

  • Expand biological replicates: Increase sample size to distinguish biological variation from technical artifacts

• Experimental design for resolution:

  • Design definitive experiments targeting the specific contradiction

  • Include appropriate positive and negative controls

  • Consider knock-down/knock-out approaches to conclusively establish specificity

  • Apply mass spectrometry to confirm protein identity in ambiguous cases

What emerging technologies might enhance PRSS33 antibody development and application?

Several cutting-edge approaches show promise for advancing PRSS33 antibody research:

• Computational antibody design: Advanced modeling approaches can enable the development of antibodies with customized specificity profiles, either with specific high affinity for PRSS33 or with controlled cross-reactivity . These computational methods can:

  • Identify optimal binding modes for different epitopes

  • Predict antibody sequences with desired specificity profiles

  • Reduce experimental screening burden through in silico predictions

• Single-cell analysis technologies: These approaches can reveal cell-specific expression patterns of PRSS33:

  • Single-cell proteomics to detect PRSS33 in rare cell populations

  • Spatial transcriptomics to map PRSS33 expression within tissues

  • Imaging mass cytometry for simultaneous detection of PRSS33 and other markers

• Proximity labeling approaches: These can identify PRSS33 interaction partners and substrates:

  • BioID or APEX2 fusion proteins to identify proximal proteins

  • Activity-based protein profiling to identify active PRSS33 in complex samples

  • Substrate trapping mutants to capture transient enzyme-substrate interactions

• Nanobody and alternative scaffold technologies: These offer advantages for certain applications:

  • Smaller size for improved tissue penetration

  • Access to cryptic epitopes inaccessible to conventional antibodies

  • Enhanced stability for harsh experimental conditions

• Multiplexed detection systems:

  • Sequential immunofluorescence to co-localize PRSS33 with multiple markers

  • Mass cytometry for high-parameter analysis

  • DNA-barcoded antibodies for highly multiplexed protein detection

How might PRSS33 research contribute to understanding disease mechanisms?

PRSS33 research has significant potential to illuminate various disease mechanisms:

• Cancer biology: Research on related proteases has shown altered expression in hepatocellular carcinoma, with prognostic significance . PRSS33 investigation may reveal:

  • Roles in tumor progression and metastasis

  • Potential as a biomarker for early detection or prognosis

  • Involvement in proteolytic cascades affecting tumor microenvironment

• Inflammatory disorders: As a serine protease, PRSS33 may participate in:

  • Regulation of inflammatory mediators

  • Immune cell activation and recruitment

  • Tissue remodeling during inflammatory resolution

• Digestive system function: Given the role of many serine proteases in digestion, PRSS33 may contribute to:

  • Nutrient processing and absorption

  • Intestinal barrier maintenance

  • Microbiome interactions

• Signaling pathway modulation: PRSS33-mediated proteolysis might regulate:

  • Growth factor activation or inactivation

  • Receptor shedding or processing

  • Extracellular matrix remodeling affecting signaling

• Research approach considerations:

  • Develop conditional knockout models to study tissue-specific functions

  • Identify physiological substrates through proteomics approaches

  • Characterize PRSS33 processing and its regulation in different physiological states

  • Investigate potential therapeutic targeting strategies